Dr. Lerner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave 3rd FL
Moakley Hematologyoncology
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Summary
- Dr. Adam Lerner is an oncologist in Boston, MA. He received his medical degree from Yale University School of Medicine and has been in practice 34 years, primarily at Boston University and Boston Medical Center. He has carried out translational research on cyclic nucleotide phosphodiesterase inhibitors as well as on a focal adhesion complex adapter protein, BCAR3/AND-34. He specializes in hematologic oncology, cutaneous oncology and soft tissue sarcomas.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1991
- Boston University Medical CenterResidency, Pathology-Anatomic and Clinical, 1986 - 1987
- Boston University Medical CenterResidency, Internal Medicine, 1983 - 1986
- Yale School of MedicineClass of 1983
- Amherst CollegeA.B., Biology, 1979
Certifications & Licensure
- MA State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- DOD Breast Cancer Idea Award 2001
- Career Development Award American Society of Clinical Oncology, 1998
- Leukemia Society of America Translational Research Award 1997
- Join now to see all
Clinical Trials
- Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Apr 01
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
- Everolimus in Treating Cutaneous T-cell Lymphoma Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19.Meredith Halpin, Adam Lerner, Manish Sagar, Praveen Govender, Bhavesh Shah
Medrxiv. 2023-06-06 - 1 citationsPrimary intracranial extraosseous Ewing's sarcoma of the skull base in an elderly adult: illustrative case.Kristine Ravina, Sonora A Windermere, Qing Zhao, Adam Lerner, Michael Dyer
Journal of Neurosurgery. Case Lessons. 2022-10-17 - 2 citationsStandard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Am...David M Hughes, Lynnette Henshaw, Frances Blevins, Camille Edwards, Adam Lerner
Clinical Lymphoma, Myeloma & Leukemia. 2022-08-01
Journal Articles
- AND-34/BCAR3 augments the ability of p130Cas to bind the Src SH3 domain in a BCAR3-p130Cas complex-dependent mannerMakkinje A, VandenBorre P, Near RI, Patel P and Lerner A, J. Biol. Chem, 1/1/2012
- Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphomaSchieke SM, Sharaf M, Lerner A, Runger T, Mahalingam M, J. Cutan. Pathol, 1/1/2012
- Complete response of metastatic hidradenocarcinoma to capecitabineLerner A, Beckford A, Ugent S, Goldberg L, Jalisi S and Demierre MF, Archives of Derm, 1/1/2011
- Join now to see all
Books/Book Chapters
Press Mentions
- Matthew Kulke, MD, Joins BUMCNovember 21st, 2017
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: